Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
BVS

BVS - Bioventus Inc. Stock Price, Fair Value and News

$7.75-0.17 (-2.15%)
Market Closed

41/100

BVS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

41/100

BVS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$7.1

Target 3M

$7.78

Target 6M

$7.54

BVS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BVS Price Action

Last 7 days

-3.1%

Last 30 days

2.9%

Last 90 days

14.5%

Trailing 12 Months

-25.6%

BVS RSI Chart

BVS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BVS Valuation

Market Cap

515.2M

Price/Earnings (Trailing)

50.65

Price/Sales (Trailing)

0.91

EV/EBITDA

37.48

Price/Free Cashflow

9.64

BVS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$7.1

Target 3M

$7.78

Target 6M

$7.54

BVS Fundamentals

BVS Revenue

Revenue (TTM)

563.8M

Rev. Growth (Yr)

-0.23%

Rev. Growth (Qtr)

-6.1%

BVS Earnings

Earnings (TTM)

10.2M

Earnings Growth (Yr)

161.08%

Earnings Growth (Qtr)

-57.7%

BVS Profitability

EBT Margin

2.61%

Return on Equity

6.12%

Return on Assets

1.45%

Free Cashflow Yield

10.38%

BVS Investor Care

Shares Dilution (1Y)

3.50%

Diluted EPS (TTM)

0.16

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025567.7M564.1M563.8M0
2024522.7M536.9M555.1M573.3M
2023513.9M510.6M502.8M512.3M
2022466.4M496.9M516.7M512.1M
2021324.3M376.1M399.1M430.9M
2020335.4M330.7M325.9M321.2M
2019000340.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About Bioventus Inc.

BVS
Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices used for precise bone sculpting, removing tumors, and tissue debridement. The company's restorative therapies include a bone healing system; skin allografts; and products that are used to support healing of wounds, as well as devices designed to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
 CEO
 WEBSITEbioventus.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES950

Bioventus Inc. Frequently Asked Questions

BVS is the stock ticker symbol of Bioventus Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Bioventus Inc. is 515.24 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check BVS's fair value in chart for subscribers.

The fair value guage provides a quick view whether BVS is over valued or under valued. Whether Bioventus Inc. is cheap or expensive depends on the assumptions which impact Bioventus Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BVS.

As of Wed Jan 28 2026, BVS's PE ratio (Price to Earnings) is 50.65 and Price to Sales (PS) ratio is 0.91. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BVS PE ratio will change depending on the future growth rate expectations of investors.